Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity

International Immunology

Volumn 27, Issue 12, 2015, Pages 621-632

  Siew, Yin Yin ^a   Neo, Soek Ying ^a   Yew, Hui Chuing ^a   Lim, Shun Wei ^a   Ng, Yi Cheng ^a   Lew, Si Min ^a   Seetoh, Wei Guang ^a   Seow, See Voon ^b,c   Koh, Hwee Ling ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Cytotoxicity; Immunogenic cell death; Natural killer cells; Ovarian cancer; Oxaliplatin; Stress ligands

Indexed keywords

ANTIGEN; BINDING PROTEIN; CD155 ANTIGEN; CISPLATIN; DNAM 1 PROTEIN; HLA A ANTIGEN; HLA B ANTIGEN; INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; OXALIPLATIN; RANTES; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UL16 BINDING PROTEIN 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN; PLATINUM COMPLEX; POLIOVIRUS RECEPTOR; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; ULBP3 PROTEIN, HUMAN; VIRUS RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CELL GROWTH; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; EC50; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LEUKOCYTE; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; CYTOTOXICITY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PHYSIOLOGICAL STRESS; TRANSPLANTATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, VIRUS; STRESS, PHYSIOLOGICAL;

EID: 84950108953     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxv041     Document Type: Article

References (69)

1. Hennessy, B. T., Coleman, R. L. and Markman, M. 2009. Ovarian cancer. Lancet 374:1371.
2. Jelovac, D. and Armstrong, D. K. 2011. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 61:183.
3. DeSantis, C. E., Lin, C. C., Mariotto, A. B. et al. 2014. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 64:252.
4. Gilks, C. B. and Prat, J. 2009. Ovarian carcinoma pathology and genetics: recent advances. Hum. Pathol. 40:1213.
5. Nik, N. N., Vang, R., Shih, I.-M. and Kurman, R. J. 2014. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu. Rev. Pathol. 9:27.
6. Tan, T. Z., Miow, Q. H., Huang, R. Y. et al. 2013. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol. Med. 5:983.
7. The Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609.
8. Coleman, R. L., Monk, B. J., Sood, A. K. and Herzog, T. J. 2013. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 10:211.
9. Katsumata, N., Yasuda, M., Takahashi, F. et al.; Japanese Gynecologic Oncology Group. 2009. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331.
10. Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E. et al. 2010. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28:3323.
11. Vaughan, S., Coward, J. I., Bast, R. C., Jr et al. 2011. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11:719.
12. Mateo, J., Ong, M., Tan, D. S., Gonzalez, M. A. and de Bono, J. S. Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nat. Rev. Clin. Oncol. 10:688.
13. Banerjee, S. and Kaye, S. B. 2013. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin. Cancer Res. 19:961.
14. Burger, R. A., Brady, M. F., Bookman, M. A. et al.; Gynecologic Oncology Group. 2011. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365:2473.
15. Perren, T. J., Swart, A. M., Pfisterer, J. et al.; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365:2484.
16. Armstrong, D. K., White, A. J., Weil, S. C., Phillips, M. and Coleman, R. L. 2013. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol. Oncol. 129:452.
17. Brahmer, J. R., Tykodi, S. S., Chow, L. Q. et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455.
18. Kershaw, M. H., Westwood, J. A., Parker, L. L. et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12(20 Pt 1):6106.
19. Berg, M., Lundqvist, A., McCoy, P., Jr et al. 2009. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11:341.
20. Geller, M. A., Cooley, S., Judson, P. L. et al. 2011. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98.
21. Chabner, B. A. and Roberts, T. G., Jr. 2005. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5:65.
22. Kroemer, G., Galluzzi, L., Kepp, O. and Zitvogel, L. 2013. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31:51.
23. Zitvogel, L., Kepp, O. and Kroemer, G. 2011. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8:151.
24. Gasser, S., Orsulic, S., Brown, E. J. and Raulet, D. H. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:1186.
25. Obeid, M., Tesniere, A., Ghiringhelli, F. et al. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13:54.
26. Apetoh, L., Ghiringhelli, F., Tesniere, A. et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13:1050.
27. Ma, Y., Adjemian, S., Mattarollo, S. R. et al. 2013. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38:729.
28. Graham, J., Mushin, M. and Kirkpatrick, P. 2004. Oxaliplatin. Nat. Rev. Drug Discov. 3:11.
29. Kelland, L. 2007. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7:573.
30. Tesniere, A., Schlemmer, F., Boige, V. et al. 2010. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:482.
31. Piccart, M. J., Green, J. A., Lacave, A. J. et al. 2000. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J. Clin. Oncol. 18:1193.
32. Ray-Coquard, I., Weber, B., Cretin, J. et al.; GINECO group. 2009. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br. J. Cancer 100:601.
33. Ljunggren, H. G. and Malmberg, K. J. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7:329.
34. Moretta, A., Bottino, C., Vitale, M. et al. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19:197.
35. Bauer, S., Groh, V., Wu, J. et al. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727.
36. Mou, X., Zhou, Y., Jiang, P. et al. 2014. The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients. Sci. Rep. 4:6138.
37. Brandt, C. S., Baratin, M., Yi, E. C. et al. 2009. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206:1495.
38. Villegas, F. R., Coca, S., Villarrubia, V. G. et al. 2002. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35:23.
39. Bamias, A., Tsiatas, M. L., Kafantari, E. et al. 2007. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol. Oncol. 106:75.
40. Fujisaki, H., Kakuda, H., Shimasaki, N. et al. 2009. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69:4010.
41. Cho, D., Shook, D. R., Shimasaki, N., Chang, Y. H., Fujisaki, H. and Campana, D. 2010. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin. Cancer Res. 16:3901.
42. Sistigu, A., Yamazaki, T., Vacchelli, E. et al. 2014. Cancer cellautonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20:1301.
43. Critchley-Thorne, R. J., Simons, D. L., Yan, N. et al. 2009. Impaired interferon signaling is a common immune defect in human cancer. Proc. Natl Acad. Sci. USA 106:9010.
44. Hato, S. V., Khong, A., de Vries, I. J. and Lesterhuis, W. J. 2014. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin. Cancer Res. 20:2831.
45. Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A. et al. 2005. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051.
46. Iliopoulou, E. G., Kountourakis, P., Karamouzis, M. V. et al. 2010. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol. Immunother. 59:1781.
47. Geller, M. A., Knorr, D. A., Hermanson, D. A. et al. 2013. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy 15:1297.
48. Ménard, C., Blay, J. Y., Borg, C. et al. 2009. Natural killer cell IFNgamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 69:3563.
49. Liu, Y., Wu, H. W., Sheard, M. A. et al. 2013. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin. Cancer Res. 19:2132.
50. Reiners, K. S., Topolar, D., Henke, A. et al. 2013. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 121:3658.
51. Waldhauer, I. and Steinle, A. 2008. NK cells and cancer immunosurveillance. Oncogene 27:5932.
52. Zitvogel, L., Tesniere, A. and Kroemer, G. 2006. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6:715.
53. Hilpert, J., Grosse-Hovest, L., Grünebach, F. et al. 2012. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J. Immunol. 189:1360.
54. McGilvray, R. W., Eagle, R. A., Watson, N. F. et al. 2009. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin. Cancer Res. 15:6993.
55. Lundqvist, A., Abrams, S. I., Schrump, D. S. et al. 2006. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factorrelated apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 66:7317.
56. Chan, C. J., Andrews, D. M., McLaughlin, N. M. et al. 2010. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 184:902.
57. Carlsten, M., Björkström, N. K., Norell, H. et al. 2007. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67:1317.
58. Fregni, G., Perier, A., Pittari, G. et al. 2011. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin. Cancer Res. 17:2628.
59. Fregni, G., Messaoudene, M., Fourmentraux-Neves, E. et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One 8:e76928.
60. Zhang, B., Kracker, S., Yasuda, T. et al. 2012. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148:739.
61. Bae, J. H., Kim, J. Y., Kim, M. J. et al. 2010. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J. Immunother. 33:391.
62. Vantourout, P., Willcox, C., Turner, A. et al. 2014. Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. Sci. Transl. Med. 6:231ra49.
63. Hervieu, A., Rébé, C., Végran, F. et al. 2013. Dacarbazinemediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J. Invest. Dermatol. 133:499.
64. Soriani, A., Zingoni, A., Cerboni, C. et al. 2009. ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113:3503.
65. Armeanu, S., Bitzer, M., Lauer, U. M. et al. 2005. Natural killer cellmediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65:6321.
66. Mimura, K., Kamiya, T., Shiraishi, K. et al. 2014. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int. J. Cancer 135:1390.
67. Martins, I., Kepp, O., Schlemmer, F. et al. 2011. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30:1147.
68. Vici, P., Sergi, D., Pizzuti, L. et al. 2013. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. J. Exp. Clin. Cancer Res. 32:49.
69. Stein, S. M., Tiersten, A., Hochster, H. S. et al. 2013. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int. J. Gynecol. Cancer 323:1577.